Sarepta Therapeutics, Inc. (SRPT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Product revenues, net | - | 374,985 | - | |
| Elevidys-rest of world | - | 374,985 | - | |
| Us | - | 185,828 | - | |
| Rest of world | - | 50,710 | - | |
| Pmo products | - | 236,538 | - | |
| Total revenues | 611,091 | 744,856 | 467,172 | |
| Selling, general and administrative | 137,897 | 133,629 | 128,200 | |
| Research and development | 204,392 | 773,448 | 224,483 | |
| Amortization of in-licensed rights | 667 | 601 | 602 | |
| Cost of sales (excluding amortization of in-licensed rights) | 152,558 | 137,564 | 91,691 | |
| Total cost and expenses | 495,514 | 1,045,242 | 444,976 | |
| Operating income (loss) | 115,577 | -300,386 | 22,196 | |
| Other income (expense), net | 38,061 | -83,132 | 11,810 | |
| Nonoperating income (expense) | - | - | 11,810 | |
| Income (loss) before income tax expense | 153,638 | -383,518 | 34,006 | |
| Income tax (benefit) expense | -43,254 | 63,990 | 395 | |
| Segment net income (loss) | 196,892 | -447,508 | 33,611 | |
| Unrealized (losses) gains on investments, net of tax | -85 | - | 3,275 | |
| Total other comprehensive (loss) income | -85 | - | 3,275 | |
| Comprehensive income (loss) | 196,807 | -447,508 | 36,886 | |
| Basic | 98,005,000 | 97,362,000 | 95,390,000 | |
| Diluted | 1.89 | -4.6 | 0.34 | |
| Diluted | 106,623,000 | 97,362,000 | 100,448,000 | |
| Earnings (loss) per common share, basic | 2.01 | -4.6 | 0.35 | |